Wu Jun
Center for Comparative Medicine, Beckman Research Institute of the City of Hope, 1500 East Duarte Rd, Duarte, CA 91010, USA.
J Pers Med. 2021 Aug 6;11(8):771. doi: 10.3390/jpm11080771.
Chemotherapy for human solid tumors in clinical practice is far from satisfactory. Despite the discovery and synthesis of hundreds of thousands of anticancer compounds targeting various crucial units in cancer cell proliferation and metabolism, the fundamental problem is the lack of targeting delivery of these compounds selectively into solid tumor tissue to maintain an effective concentration level for a certain length of time for drug-tumor interaction to execute anticancer activities. The enhanced permeability and retention effect (EPR effect) describes a universal pathophysiological phenomenon and mechanism in which macromolecular compounds such as albumin and other polymer-conjugated drugs beyond certain sizes (above 40 kDa) can progressively accumulate in the tumor vascularized area and thus achieve targeting delivery and retention of anticancer compounds into solid tumor tissue. Targeting therapy via the EPR effect in clinical practice is not always successful since the strength of the EPR effect varies depending on the type and location of tumors, status of blood perfusion in tumors, and the physical-chemical properties of macromolecular anticancer agents. This review highlights the significance of the concept and mechanism of the EPR effect and discusses methods for better utilizing the EPR effect in developing smarter macromolecular nanomedicine to achieve a satisfactory outcome in clinical applications.
在临床实践中,用于治疗人类实体瘤的化疗效果远不尽人意。尽管已发现并合成了数十万种针对癌细胞增殖和代谢中各种关键环节的抗癌化合物,但根本问题在于缺乏将这些化合物选择性地靶向递送至实体瘤组织的方法,从而无法在一定时间内维持有效浓度水平,以实现药物与肿瘤的相互作用并发挥抗癌活性。增强的渗透与滞留效应(EPR效应)描述了一种普遍的病理生理现象及机制,即诸如白蛋白等大分子化合物以及其他超过一定尺寸(40 kDa以上)的聚合物偶联药物能够逐渐在肿瘤血管化区域蓄积,进而实现抗癌化合物在实体瘤组织中的靶向递送与滞留。在临床实践中,通过EPR效应进行靶向治疗并非总是成功的,因为EPR效应的强度会因肿瘤的类型和位置、肿瘤的血液灌注状况以及大分子抗癌药物的物理化学性质而有所不同。本综述强调了EPR效应概念和机制的重要性,并讨论了在开发更智能的大分子纳米药物以在临床应用中取得满意疗效时更好地利用EPR效应的方法。